Cigna's Evernorth to Offer Humira Biosimilar Without Out-of-Pocket Fee
By Ben Glickman
Cigna Group-owned Evernorth Health Services said Thursday it would provide a Humira biosimilar with no out-of-pocket fees starting in June.
The pharmacy and benefits provider said the biosimilar for Humira, used as a treatment for rheumatoid arthritis, Crohn's disease and other inflammatory conditions, would be available to eligible patients at its specialty pharmacy Accredo.
The company said the biosimilar price would be about 85% lower than the Humira list price. Evernorth said more than 100,000 Accredo patients currently use Humira or a biosimilar.
Plans for a $0 out-of-pocket Humira biosimilar offering was initially announced by Evernorth in March.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 25, 2024 17:25 ET (21:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations